This 10-year follow-up confirms the non-inferiority of the ultra-hypofractionated radiotherapy regimen compared with the conventionally fractionated, with similar toxicity profiles. The findings support the seven-fraction schedule as a safe, effective, and practical standard-of-care option for patients with intermediate-risk prostate cancer.
[Articles] Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial
The Lancet Oncology | | Per Nilsson, Adalsteinn Gunnlaugsson, Lars Beckman, Anders Widmark, Per Fransson, Morten Hoyer, Magnus Lagerlund, Jon Kindblom, Bengt Johansson, Kirsten Björnlinger, Claes Ginman, Martha Olsson, Måns Agrup, Elisabeth Kjellén, Björn Zackrisson, Björn Tavelin, Lars Franzén, Harald Anderson, Camilla Thellenberg Karlsson
Topics: prostate-cancer, blood-cancer, radiation, clinical-trials, research